福元药业申请药物临床试验的酮洛芬凝胶贴膏，适应症为适用于下列疾病和症状的镇痛及消炎：骨关节 炎、肩周炎、肌腱及肌腱炎、肌腱周围炎、肱骨外上髁炎(网球肘等)、肌肉痛、外伤后肿胀及疼痛。给 药途径为局部，注册分类属化学药品3类。截至目前，福元药业对本品已投入研发费用约人民币396.76 万元(未经审计)。 福元医药（601089）(601089.SH)发布公告，近日，公司全资子公司福元药业有限公司(简称"福元药业") 收到了国家药品监督管理局核准签发的酮洛芬凝胶贴膏的《药物临床试验批准通知书》。 ...

福元药业申请药物临床试验的酮洛芬凝胶贴膏，适应症为适用于下列疾病和症状的镇痛及消炎：骨关节 炎、肩周炎、肌腱及肌腱炎、肌腱周围炎、肱骨外上髁炎(网球肘等)、肌肉痛、外伤后肿胀及疼痛。给 药途径为局部，注册分类属化学药品3类。截至目前，福元药业对本品已投入研发费用约人民币396.76 万元(未经审计)。 智通财经APP讯，福元医药(601089.SH)发布公告，近日，公司全资子公司福元药业有限公司(简称"福元 药业")收到了国家药品监督管理局核准签发的酮洛芬凝胶贴膏的《药物临床试验批准通知书》。 ...

Group 1 - The core viewpoint of the news is that Fuyuan Pharmaceutical's stock has increased by 5.01%, reaching a price of 25.76 yuan per share, with a trading volume of 432 million yuan and a turnover rate of 3.65%, resulting in a total market capitalization of 12.365 billion yuan [1] - Fuyuan Pharmaceutical, established on February 3, 1999, is located in Tongzhou District, Beijing, and was listed on June 30, 2022. The company's main business involves the research, production, and sales of pharmaceutical preparations and medical devices, with pharmaceutical preparations accounting for 94.09% of revenue and medical devices 6.00% [1] Group 2 - Among the top ten circulating shareholders of Fuyuan Pharmaceutical, a fund under E Fund ranks as a significant shareholder. The E Fund Healthcare Industry Mixed A (110023) entered the top ten circulating shareholders in the third quarter, holding 2.5638 million shares, which represents 0.53% of the circulating shares. The estimated floating profit today is approximately 3.1535 million yuan [2] - The E Fund Healthcare Industry Mixed A (110023) was established on January 28, 2011, with a latest scale of 3.802 billion yuan. Year-to-date returns are 39.49%, ranking 1421 out of 8130 in its category; the one-year return is 35.06%, ranking 1969 out of 8054; and since inception, the return is 324.9% [2] - The fund manager of E Fund Healthcare Industry Mixed A is Yang Zhenshao, who has been in the position for 9 years and 102 days. The total asset scale under management is 9.816 billion yuan, with the best fund return during the tenure being 215.53% and the worst being -12.11% [2]

Core Viewpoint - Fu Yuan Pharmaceutical's stock has shown significant growth this year, with a year-to-date increase of 61.36% and a recent uptick in trading activity, indicating strong market interest and potential investment opportunities [1][2]. Company Overview - Fu Yuan Pharmaceutical, established on February 3, 1999, and listed on June 30, 2022, is located in Tongzhou District, Beijing. The company specializes in the research, production, and sales of pharmaceutical preparations and medical devices, with 94.09% of its revenue coming from pharmaceutical preparations and 6.00% from medical devices [1][2]. Financial Performance - For the period from January to September 2025, Fu Yuan Pharmaceutical reported a revenue of 2.52 billion yuan, a year-on-year decrease of 1.04%, and a net profit attributable to shareholders of 375 million yuan, down 6.39% compared to the previous year [2][3]. - The company has distributed a total of 661 million yuan in dividends since its A-share listing [3]. Shareholder Information - As of September 30, 2025, the number of shareholders for Fu Yuan Pharmaceutical was 22,700, a decrease of 3.39% from the previous period. The average number of circulating shares per shareholder increased by 3.51% to 21,153 shares [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited is the fourth largest, holding 4.25 million shares, a reduction of 1.25 million shares from the previous period. New entrants include E Fund Healthcare Industry Mixed A and Ping An New Xin Pioneer Mixed A, holding 2.56 million and 2.12 million shares, respectively [3]. Market Activity - On November 27, Fu Yuan Pharmaceutical's stock price rose by 2.04% to 25.03 yuan per share, with a trading volume of 384 million yuan and a turnover rate of 3.25%, resulting in a total market capitalization of 12.01 billion yuan [1]. - The stock has appeared on the "Dragon and Tiger List" four times this year, with the most recent occurrence on September 5, where it recorded a net buy of -42.23 million yuan [1].

Core Viewpoint - The chemical pharmaceutical sector experienced a rise of 1.66% on November 26, with Frontier Biotech leading the gains, while the overall Shanghai Composite Index fell by 0.15% [1]. Group 1: Stock Performance - Frontier Biotech (688221) closed at 20.20, up 12.85% with a trading volume of 455,500 shares and a transaction value of 916 million yuan [1]. - Yuyuan Pharmaceutical (688658) closed at 26.88, up 12.00% with a trading volume of 218,600 shares and a transaction value of 577 million yuan [1]. - Fuyuan Pharmaceutical (6801089) closed at 24.53, up 10.00% with a trading volume of 113,800 shares and a transaction value of 274 million yuan [1]. - Other notable performers include Guangji Pharmaceutical (000952) with a 9.99% increase and Beida Pharmaceutical (000788) with a 9.94% increase [1]. Group 2: Fund Flow Analysis - The chemical pharmaceutical sector saw a net inflow of 43.08 million yuan from institutional investors, while retail investors contributed a net inflow of 23.8 million yuan [2]. - The sector experienced a net outflow of 281 million yuan from speculative funds [2]. - Key stocks with significant fund flows include Heng Rui Pharmaceutical (600276) with a net inflow of 231 million yuan from institutional investors [3]. Group 3: Individual Stock Fund Flow - New China Pharmaceutical (000756) had a net inflow of 68.2 million yuan from institutional investors, while experiencing a net outflow of 21.7 million yuan from speculative funds [3]. - Fuyuan Pharmaceutical (601089) saw a net inflow of 67.6 million yuan from institutional investors, with a net outflow of 39.4 million yuan from speculative funds [3]. - Other stocks like Beibete (688759) and Yuyuan Pharmaceutical (688658) also showed varying levels of net inflows and outflows from different investor categories [3].

Core Points - The Shanghai Composite Index closed at 3864.18 points, below the five-day moving average, with a decline of 0.15% [1] - The total trading volume of A-shares reached 1,797.19 billion yuan [1] - A total of 693 A-shares broke through the five-day moving average today, with notable stocks showing significant deviation rates [1] Summary by Category Stock Performance - Mingwei Electronics (688699) saw a price increase of 20.01% with a deviation rate of 15.61% [1] - Dongxin Co., Ltd. (688110) also increased by 20.00%, with a deviation rate of 14.05% [1] - Ningbo Color Masterbatch (301019) rose by 20.00%, showing a deviation rate of 12.63% [1] Trading Activity - The trading turnover rate for Mingwei Electronics was 6.94% [1] - Dongxin Co., Ltd. had a turnover rate of 11.72% [1] - Ningbo Color Masterbatch recorded a turnover rate of 16.34% [1] Deviation Rate Rankings - Other notable stocks with high deviation rates include: - Huanle Home (300997) with a deviation rate of 12.38% [1] - Zhu Laoliu (920726) at 10.64% [1] - Haitong Development (603162) at 8.63% [1]

（文章来源：证券时报网） | 证券代 | 证券简 | 今日涨跌幅 | 今日换手率 | 半年线 | 最新价 | 乖离率 | | --- | --- | --- | --- | --- | --- | --- | | 码 | 称 | （%） | （%） | （元） | （元） | （%） | | 601089 | 福元医 药 | 10.00 | 2.37 | 22.37 | 24.53 | 9.66 | | 600868 | 梅雁吉 祥 | 10.10 | 2.23 | 2.88 | 3.16 | 9.62 | | 688658 | 悦康药 业 | 12.00 | 4.86 | 24.55 | 26.88 | 9.49 | | 688209 | 英集芯 | 11.93 | 5.68 | 19.68 | 21.48 | 9.17 | | 002187 | 广百股 份 | 9.95 | 6.05 | 6.60 | 7.18 | 8.80 | | 920726 | 朱老六 | 13.18 | 21.64 | 20.63 | 22.41 | 8.62 | | 600227 | 赤天化 | 10.16 | 7.49 | 2 ...

Group 1 - Four companies have received court approval for restructuring investments [2] - Aowannianqing's product, Zhongzubei Dingchuan Wan, focuses on treating respiratory issues [2] - Beida Pharmaceutical has expanded its business scope to include both chemical synthesis and biopharmaceuticals [2] - Zhongheng Group's subsidiary acquired a technology for treating chronic heart failure for 55 million yuan [2] - Huaren Health is focused on the pharmaceutical distribution industry, with Alibaba Health as a significant shareholder [2] - Haiwang Biological is one of the largest national pharmaceutical commercial enterprises in China [2] - Fuyuan Pharmaceutical's Lansoprazole enteric-coated capsules have been approved for registration [2] - People's Tongtai is the largest pharmaceutical commercial company in Heilongjiang Province [2] - Yinghe Group is a regional leader in pharmaceutical distribution in Zhejiang Province [2] - Ruikang Pharmaceutical has completed special item approval for the import of Evusheld, a COVID-19 prevention drug [2] - Jindike is one of the first companies to achieve the approval and sale of quadrivalent influenza vaccines [2] Group 2 - Dairong has completed the transfer of shares with Zhongdao Chenying [3] - Boyong Generation is a leader in the domestic ETC chip field [3] - Wantong Development plans to invest 854 million yuan to acquire a 62.98% stake in Shudu Technology [3] - Mingwei Electronics collaborates with major manufacturers for chip production [3] - Qipilong is a leading Chinese men's clothing brand [3] - Dongxin Co. is one of the few companies in mainland China providing complete solutions for NAND, NOR, and DRAM chips [3] - The National Space Administration has issued a plan to promote the high-quality development of commercial aerospace [3] - Sanwei Tiandi has clients including China Aerospace for its digital inspection and testing management services [3] - Leike Defense has developed a comprehensive satellite application business [3] - Tianqimo has sufficient orders for its aviation parts business [3] Group 3 - The implementation plan to enhance the adaptability of supply and demand for consumer goods has been issued [4] - Maoye Commercial is a retail market leader in Hohhot [4] - Jialinjie is a leader in functional fabrics for outdoor sports [4] - Xueqi Electric specializes in the production of refrigerators and commercial display cabinets [4] - Guangbai Co. is the largest department store chain in Guangzhou [4] - Mengjie Co. has launched the first children's home textile brand in the industry [4] - Juran Smart Home has signed a strategic cooperation agreement following the chairman's passing [4] - Haixin Food is a leading company in the frozen fish ball market [4] - Sanjiang Shopping is the largest local supermarket chain in Zhejiang Province [4] - Jiangxi Province's first listed company in the commercial circulation industry is Guoguang Chain [4] Group 4 - The company is a leading e-commerce platform for liquor, with various brand partnerships [5] - Shiji Group plans to acquire a 95% stake in Fujian Shuchuan Ming Shang for 184.6 million yuan [5] - Laizhi Group specializes in new materials for construction additives [5] - Dahua Intelligent has developed a complete quantum secure satellite internet communication solution [5] - Haitong Development operates dry bulk shipping services across over 200 ports [5] - Qingshan Paper is a major supplier of optical communication modules and components [5] Group 5 - Ningbo Color Masterbatch has launched a high-transparency POE film crosslinking masterbatch [6] - BOLE FREE STARS' app surpassed 10 million downloads in its first week [6] - Hainan Free Trade Port is set to launch on December 18 [6] - Hainan Ruize focuses on concrete and new wall materials production [6] - Tianpu Co. has completed the transfer of shares with Zhonghuang Chenying [6] - Longsao Technology has increased its sales contract for lithium iron phosphate materials significantly [6] Group 6 - The company has developed energy storage products covering various systems and collaborated with international wind power leaders [7] - Huanyue Century has established an AI joint laboratory for content production [7] - Luoping Zinc Electric is the only enterprise in the zinc smelting industry with a tri-production model [7] - Meiyan Jixiang operates seven hydropower stations in Guangdong [7] - Qingshang Co. has developed smart city products using streetlights as a platform [7] - Meike Home focuses on domestic retail and international wholesale of home products [7] Group 7 - Chitianhua is the largest methanol producer in Guizhou, with an annual capacity of 300,000 tons [8] - Weiyuan Co. is the largest producer of phenol and acetone in China [8] - Teli A is controlled by the Shenzhen State-owned Assets Supervision and Administration Commission [8] - Hongmian Co. is a state-owned enterprise in Guangzhou focusing on daily chemical products [8] - Zhonghuan Hailu produces various industrial metal forgings for multiple sectors [8]

Core Points - The Shanghai Composite Index is at 3868.16 points, slightly down by 0.05%, with total A-share trading volume at 1.4667 trillion yuan [1] - 100 A-shares have surpassed the half-year line today, with notable stocks showing significant deviation rates [1] Summary by Category Market Performance - The Shanghai Composite Index is currently above its half-year line, indicating a stable market performance [1] - The total trading volume of A-shares reached 1.4667 trillion yuan, reflecting active market participation [1] Notable Stocks - Stocks with the highest deviation rates from the half-year line include: - Yingjixin (688209) with a deviation rate of 9.77% and a price increase of 12.56% [1] - Fuyuan Pharmaceutical (601089) with a deviation rate of 9.66% and a price increase of 10.00% [1] - Meiyan Jixiang (600868) with a deviation rate of 9.62% and a price increase of 10.10% [1] - Other stocks with significant performance include: - Guangbai Co. (002187) with a 9.95% increase and a deviation rate of 8.80% [1] - Chitianhua (600227) with a 10.16% increase and a deviation rate of 8.44% [1] Additional Stocks - Other notable stocks with positive performance and deviation rates include: - Yuekang Pharmaceutical (688658) with a 10.88% increase and a deviation rate of 8.40% [1] - Haiwang Biological (000078) with a 10.20% increase and a deviation rate of 7.79% [1] - Stocks with lower deviation rates but still above the half-year line include: - Guizhou Maotai and China Medical with minor deviations, indicating a stable position [1]

Core Points - The Shanghai Composite Index is at 3869.21 points, slightly above the five-day moving average, with a change of -0.02% [1] - The total trading volume of A-shares today is 146.13 billion yuan [1] - A total of 832 A-shares have surpassed the five-day moving average, with notable stocks showing significant deviation rates [1] Summary by Category Stock Performance - Mingwei Electronics (688699) has the highest deviation rate at 15.61%, with a daily increase of 20.01% and a turnover rate of 6.03% [1] - Haitong Development (603162) and Qingshan Paper (600103) follow with deviation rates of 8.63% and 8.56%, respectively, both showing daily increases of over 9% [1] - Other notable stocks with significant daily increases include Xueqi Electric (001387) at 10.04% and Huashu Holdings (000509) at 10.11% [1] Deviation Rate Rankings - The top stocks with the highest deviation rates from the five-day moving average include: - Mingwei Electronics: 15.61% - Haitong Development: 8.63% - Qingshan Paper: 8.56% [1] - Additional stocks with notable performance include: - Xueqi Electric: 8.20% - Huashu Holdings: 8.16% [1]